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Clinical Significance of Free-to-Total Prostate-Specific Antigen 
(PSA) Ratio in Advanced Prostate Cancer Patients with PSA Less 
than 0.1 ng/ml after Hormone Treatment
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Department of Urology, Yonsei University Wonju College of Medicine, Wonju, Korea
Purpose: We analyzed the pattern of change in the free-to-total prostate-specific anti-
gen (f/t PSA) ratio and the progression to castration-resistant prostate cancer (CRPC) 
in patients with advanced prostate cancer who received hormone treatment and whose 
PSA nadir was below 0.1 ng/ml.
Materials and Methods: We retrospectively analyzed the medical records of 52 patients 
with advanced prostate cancer. All patients were treated with maximum androgen 
blockade (gonadotrophin-releasing hormone agonist and anti-androgen agents). The 
patients were divided into two groups: those with a nadir f/t PSA ratio above 60% and 
those with a nadir f/t PSA ratio of 60% or below. Age, initial PSA, clinical stage, lymph 
node metastasis, bone metastasis, and follow-up data, including PSA, free PSA, and 
f/t PSA ratio, were collected. The Mann-Whitney U-test, Fisher exact test, chi-square 
test, Kaplan-Meier survival analysis, and log rank test were used.
Results: There were 24 patients in the group with a nadir f/t PSA ratio above 60% and 
28 patients in the group with a nadir f/t PSA ratio of 60% or below. After hormone ther-
apy, the median f/t PSA ratio in each group increased from 37% and 34% at 3 months 
to 75% and 60% at 6 months, respectively. At 9 months, however, the f/t PSA ratio in-
creased to 80% in the group with a nadir f/t PSA ratio above 60%, whereas it decreased 
to 31% in the group with a nadir f/t PSA ratio of 60% or below. From 9 to 15 months, 
the f/t PSA ratio showed a tendency to decrease (75 to 37% and 27 to 20%, respectively). 
The progression to CRPC was significantly different between the two groups (10 vs. 
24).
Conclusions: Progression to CRPC was significantly higher in the group with a lower 
f/t PSA ratio. Additionally, the pattern of change in the f/t PSA ratio was significantly 
different after 9 months. Collectively, the f/t PSA ratio can be used as an additional 
marker for prognosis of hormone treatment.
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INTRODUCTION
Prostate cancer is the most common cancer in the United 
States [1]. In Korea, prostate cancer is the fifth most com-
mon malignancy in men [2]. Because of prostate-specific 
antigen (PSA)-based screening, the clinical stage of newly 
diagnosed prostate cancer has been migrating downward 
in the United States [3]. According to the American Cancer 
Society-National Prostate Cancer Detection Project, the 
proportion of locally advanced (clinical state T3) and meta-
static (stage T1-4N0-1M1) prostate cancer (advanced pros-
tate cancer) was reduced to less than 5% of all newly diag-
nosed cancers [4]. In Korea, however, more than half of 
newly diagnosed prostate cancer is of an advanced stage Korean J Urol 2012;53:149-153
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TABLE 1. The clinical characteristics and CRPC progression in the two groups
Characteristic Total (n=52) Group 1 (n=24) Group 2 (n=28) p-value
Age (yr)
Biopsy Gleason score 
Initial PSA (ng/ml)
Initial f/t PSA ratio (%)
Nadir f/t PSA ratio (%)
Time to PSA nadir (mo)
LN invasion (%)
Bone metastasis (%)
Progression to CRPC (%)
Time to CRPC (mo)
  75 (70-80)
7 (6-9)
     16.27 (9.32-88.06)
  8.80 (0.01-11)
  60 (60-87)
 6 (5-9)
  7 (13.4)
22 (42.3)
34 (65.3)
  15 (12-24)
  75 (55-87)
8 (7-9)
     23.53 (6.39-84.02)
10 (2-15)
  90 (80-90)
5 (4-8)
  3 (12.5)
10 (41.6)
10 (41.6)
  15 (12-24)
  75 (70-81)
6 (6-8)
       13.73 (9.32-100.00)
       6 (0.01-10)
  60 (30-60)
7 (6-9)
  4 (14.2)
12 (42.8)
24 (85.7)
  15 (12-24)
0.713
a
0.007
a
0.567
a
0.283
a
0.001
a
0.111
a
0.654
b
0.578
b
0.002
b
0.792
a
Values are presented as □  (interquarile range).
PSA, prostate-specific antigen; f/t PSA ratio, free-to-total PSA ratio; LN, lymph node; CRPC, castration-resistant prostate cancer. 
a: Mann-Whitney U-test, 
b: Fisher exact test and Chi-square test.
[5].
For localized prostate cancer, radical prostatectomy and 
radiation therapy have been the recommended treatment 
modalities [6]. Hormone treatment has been considered a 
gold standard for the treatment of advanced prostate can-
cer [7]. Hormone treatment is a feasible option as the pri-
mary treatment of choice for localized prostate cancer, de-
pending on the patient’s age at diagnosis, life expectancy, 
and socioeconomic status [5]. However, after 18 to 24 mon-
ths of hormone treatment, advanced prostate cancer pro-
gresses to castration-resistant prostate cancer (CRPC) [8]. 
Therefore, it is important to be able to forecast which pa-
tients have cancer that may progress to CRPC in order to 
improve the efficacy of hormone treatment and to perform 
additional treatments.
Recent studies have reported that changes in the 
free-to-total PSA (f/t PSA) ratio in patients with advanced 
prostate cancer whose PSA level has reached the nadir is 
an important prognostic factor. Therefore, we investigated 
the pattern of change in the f/t PSA ratio and the pro-
gression to CRPC in patients with advanced prostate can-
cer who received hormone treatment and whose PSA nadir 
was below 0.1 ng/ml. 
MATERIALS AND METHODS
We retrospectively analyzed the medical records of 52 pa-
tients who received hormone treatment after a diagnosis 
of advanced prostate cancer between January 2007 and 
April 2009. Data on age, initial PSA, clinical stage, lymph 
node metastasis, and bone metastasis were collected. The 
follow-up data of the patients included PSA, free PSA 
(fPSA), and f/t PSA ratio every 3 months for 15 months. The 
2010 American Joint Committee on Cancer/tumor-node- 
metastasis staging system and Gleason system were used 
for the pathologic staging and tumor grading [9]. The clin-
ical stage was locally advanced (T3-4) or metastatic (stage 
T1-4N0-1M1) prostate cancer. The pathologic diagnosis 
was confirmed with transrectal ultrasonography-guided 
prostate biopsy. All patients underwent magnetic reso-
nance imaging and bone scans for staging workup.
All patients were treated with maximum androgen 
blockade (gonadotrophin-releasing hormone agonist and 
anti-androgen agents) [10]. The patients who underwent 
radical prostatectomy or radiation therapy before hormone 
therapy, antiandrogen monotherapy, or other forms of che-
motherapy were excluded. According to the European 
Association of Urology Guideline, CRPC was defined as 2 
consecutive increases in PSA despite a testosterone level 
in the castration range [6]. The PSA nadir was defined as 
the lowest PSA level during hormone treatment [11,12]. 
The patients were divided into two groups with a nadir f/t 
PSA ratio above 60% (group 1) and a nadir f/t PSA ratio of 
60% or below (group 2). The pattern of change in the f/t PSA 
ratio during the course of hormone treatment and pro-
gression to CRPC were compared between the two groups.
The Mann-Whitney U-test, Fisher exact test, and chi-squ-
are test were used to compare the two groups of patients. 
Kaplan-Meier survival analysis and the log rank test was 
used to analyze the difference in progression to CRPC be-
tween the two groups. All statistical analyses were per-
formed with SPSS ver. 18.0 (IBM, New York, NY, USA), 
and p-values less than 0.05 were determined to be statisti-
cally significant.
RESULTS
Table 1 summarizes the clinical characteristics and CRPC 
progression in the two groups. The median age of the pa-
tients was 75 years (interquartile range [IQR], 70 to 80 
years), and the median Gleason score was 7 (IQR, 6 to 9). 
PSA and the f/t PSA ratio at the time of diagnosis were 16.27 
ng/ml (IQR, 9.32 to 88.06 ng/ml) and 8.80% (IQR, 0.01 to 
11.50%), respectively. The PSA nadir of all patients was 
lower than 0.1 ng/ml. The median nadir f/t PSA ratio and 
the time to PSA nadir were 60% (IQR, 60 to 87%) and 6 
months (IQR, 5 to 9 months), respectively. Progression to 
CRPC occurred in 34 patients, and the median time elapsed Korean J Urol 2012;53:149-153
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FIG. 1. The pattern of change in the free-to-total prostate-spe-
cific antigen ratio between the two groups during hormone 
treatment. 
a: p＜0.001.
FIG. 2. The probability of progression to castration-resistant 
prostate cancer (CRPC) during hormone treatment in the two 
groups.
to progression to CRPC was 15 months (IQR, 12 to 24 
months). There were 24 patients in group 1 and 28 patients 
in group 2. There were no significant differences in the me-
dian age, lymph node invasion, bone metastasis, initial 
PSA, initial f/t PSA ratio, or time to PSA nadir between the 
two groups. The median Gleason score was 8 (IQR, 7 to 9) 
in group 1 and 6 (IQR, 6 to 8) in group 2, which was statisti-
cally significant. The median nadir f/t PSA ratio was 
90.00% (IQR, 80.00 to 90.00%) in group 1 and 60% (IQR, 
30 to 60%) in group 2.
Fig. 1 shows the change in the f/t PSA ratio between the 
two groups. After PSA nadir, the median f/t PSA ratio of 
group 1 and group 2 increased from 37% (IQR, 30 to 76%) 
and 34% (IQR, 19 to 60%) at 3 months from the initiation 
of therapy to 75% (IQR, 40 to 87%) and 60% (IQR, 60 to 61%) 
at 6 months, respectively. There was no significant differ-
ence in the median f/t PSA ratio between the two groups. 
However, at 9 months, an increase in the ratio to 80% (IQR, 
55 to 100%) was observed in group 1, whereas a decrease 
to 31% (IQR, 30 to 42%) was noted in group 2 (p＜0.001). 
After 12 months, the ratio showed a tendency to decrease 
in both groups from 75% (IQR, 50 to 97%) to 37% (IQR, 27 
to 90%) in group 1 and from 27% (IQR, 20 to 40%) to 20% 
(IQR, 10 to 28%) in group 2 (p＜0.001 and 0.001, re-
spectively). The difference in the median f/t PSA ratio be-
tween the two groups was significant from 9 to 15 months 
after the time of PSA nadir.
The probability of progression to CRPC during the fol-
low-up period is illustrated in Fig. 2. The number of cases 
involving progression to CRPC was 10 in group 1 and 24 
in group 2 (p=0.002). The median time to CRPC in both 
groups was 15 months (IQR, 12 to 24 months and 12 to 24 
months, respectively), and it was not significantly different 
as shown in Table 1 (p=0.792).
DISCUSSION
In the United States, prostate cancer has the highest in-
cidence of all noncutaneous malignancies and has the sec-
ond-highest mortality rate in men [1]. Advances in screen-
ing and diagnostic techniques have resulted in a downward 
migration of stage [13]. In Korea, however, more than half 
of newly diagnosed prostate cancer is already of a locally 
advanced or metastatic stage [5]. 
Hormone therapy is the standard treatment for ad-
vanced prostate cancer [6,14]. Nonetheless, the timing of 
hormonal treatment in advanced prostate cancer remains 
controversial [6]. Although radical prostatectomy and ra-
diation therapy have been recommended in localized ad-
vanced prostate cancer [15-18], Heidenreich [19] reported 
that hormone treatment has benefits in high-risk patients, 
such as those with poorly differentiated prostate cancer 
(Gleason score of 8 to 10) and those with a very short PSA 
doubling time (＜12 months). Also, Park et al. [5] reported 
that many of those with advanced prostate cancer have 
been treated with hormone treatment for various reasons, 
such as failure of surgical or radiation treatment, age at the 
time of diagnosis, or socioeconomic status. However, most 
patients with advanced prostate cancer who have received 
hormone treatment eventually progress to CRPC, despite 
the maintenance of castration serum testosterone levels 
[8]. In the present study, patients treated with hormone 
treatment showed biochemical improvements, with PSA 
decreasing to 0.01 ng/ml or lower in an average of 6 months, 
as well as progression to CRPC in an average of 15 months. 
Therefore, it is important to detect patients who may show 
early progression to CRPC and to perform other salvage 
therapies, including secondary hormone therapy, chemo-
therapy, and radiation therapy, early.
Although the pathophysiology of prostate cancer has not 
been elucidated completely, well-known prognostic factors 
include age, Gleason score, bone pain, serum hemoglobin 
level, PSA nadir, time to PSA nadir, and PSA level 3 months Korean J Urol 2012;53:149-153
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and 6 months after treatment. However, the validity of 
these factors has not been clearly established. A previous 
report showed that Gleason score, PSA nadir, and PSA lev-
el 6 months after hormone treatment are prognostic factors 
that predict the progression to HRPC [5]. Kwak et al. [10] 
reported that the nadir PSA level after hormone treatment 
may be the most accurate prognostic factor. Huang et al. 
[20] suggested that the PSA nadir and time to PSA nadir 
are important prognostic factors. The PSA level is a useful 
marker in the diagnosis of prostate cancer, but there are 
disagreements about its prognostic importance after hor-
mone treatment. Collette et al. [21] reported that PSA 
alone is not an appropriate marker of long-term ther-
apeutic benefit in prostate cancer. Yoon [22] reported that 
free PSA is not a static factor, but rather a dynamic factor 
that is influenced by various conditions including hormone 
treatment. Therefore, free PSA and the f/t PSA ratio can 
be used to predict the prognosis of patients treated by hor-
mone treatment. In this study, the number of patients pro-
gressing to HRPC was 10 in group 1 and 14 in group 2 
(p=0.003). These findings suggest that the nadir f/t PSA ra-
tio can be a prognostic factor.
Tanaka et al. [23] reported that whereas the f/t PSA ratio 
is unaffected by the stage of prostate cancer at the time of 
diagnosis, it does rise during the period in which the cancer 
is responsive to hormone treatment and then slowly re-
turns to the pretreatment level as the cancer recurs. Recent 
literature has shown that the difference in the f/t PSA ratio 
between a group showing early biochemical recurrence and 
a group continuously responsive to hormone treatment be-
comes greater at 8 to 10 months after the initiation of treat-
ment compared with the time of diagnosis. Some authors 
have argued that the pattern of change in the f/t PSA ratio 
is dependent on the response to treatment. In this study, 
the f/t PSA ratio of both groups steadily increased until 6 
months after the initiation of hormone treatment. Howev-
er, the f/t PSA ratio continuously declined since 9 months 
in group 2, whereas it remained elevated until 9 months 
and then slowly declined in group 1. The pattern of change 
in the f/t PSA ratio is thought to be related to the response 
to hormone treatment, similar to PSA. Such results are 
consistent with the results of previous studies showing 
that the f/t PSA ratio is affected not only by hormone treat-
ment of advanced prostate cancer but also by the degree of 
response to hormone treatment. These results also demon-
strate the importance of the f/t PSA ratio as a supple-
mentary prognostic marker in the hormone treatment of 
advanced prostate cancer that can be used simultaneously 
with PSA. 
CONCLUSIONS
When patients were divided into two groups on the basis 
of the nadir f/t PSA ratio, progression to CRPC was sig-
nificantly higher in the group with a lower f/t PSA ratio. 
In addition, the pattern of change in the f/t PSA ratio was 
significantly different after 9 months. Collectively, the f/t 
PSA ratio can be used as an additional marker for the prog-
nosis of hormone treatment. Further additional large-scale 
studies elucidating the clinical significance of f/t PSA ratio 
monitoring in the hormone treatment of advanced prostate 
cancer are necessary.
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